Biobeat vs Cadence (2026)
Both watch patients who are not being watched, and they buy different things with the budget. Biobeat buys data, putting wearable continuous monitors on patients who are otherwise checked every few hours, with a genuinely strong clearance record for cuffless measurement and the widest setting coverage in its category. Cadence buys labour, running chronic care management for older adults at home in partnership with health systems, and it publishes the proportion of vitals alerts its supervised agents close without a human, which makes its supervision claim checkable rather than rhetorical. A programme with no monitoring data needs the first; one with alerts nobody works needs the second. On Biobeat, ask about skin tone, because optical measurement varies with pigmentation and its readings drive automated alerts.
- It changes what data exists, putting wearable continuous monitors on patients otherwise checked intermittently, with a progressive clearance record for cuffless measurement.
- Setting coverage is the widest in its category, spanning general wards, step down and home monitoring on one platform.
- For a hospital, continuous vitals reach deterioration that happens between observations, which periodic checks cannot see.
- It runs chronic care management for older adults at home in partnership with health systems, billed through an existing reimbursement pathway.
- It publishes the proportion of vitals alerts its supervised agents resolve without a human, with a stated review time, which makes the supervision claim checkable.
- Conditions and population are enumerated precisely, so a buyer can match the programme against its own attributed panel.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Biobeat and Cadence are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Biobeat | Cadence |
|---|---|---|
| Primary category | Inpatient Deterioration & Risk Monitoring | Remote Monitoring & Chronic Care |
| Founded | 2016 | Not recorded |
| Headquarters | Petah Tikva, Israel | New York, New York |
| Website | bio-beat.com | cadence.care |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Biobeat its top capability grade on FDA and Regulatory Status. Set against Cadence, Biobeat grades higher on FDA and Regulatory Status and Deployment Model and Data Residency. Its thinnest published disclosure sits on Model Supply Chain Disclosure and AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Cadence its top capability grade on Autonomy and Oversight Model and Clinical and Operational Evidence. Set against Biobeat, Cadence grades higher on several axes, including AI Centrality, Autonomy and Oversight Model and Clinical and Operational Evidence. Its thinnest published disclosure sits on Model Supply Chain Disclosure and AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Biobeat or Cadence?
On the axes where the AI Health Index separates them, Biobeat grades higher on FDA and Regulatory Status and Deployment Model and Data Residency, and Cadence grades higher on several axes, including AI Centrality, Autonomy and Oversight Model and Clinical and Operational Evidence. Cadence leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Biobeat and Cadence differ most?
The widest separation the AI Health Index records between Biobeat and Cadence is on Autonomy and Oversight Model, where Biobeat grades C and Cadence grades A. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do Biobeat and Cadence grade the same?
The AI Health Index grades Biobeat and Cadence the same on several axes, including Model and Technology Transparency, Model Supply Chain Disclosure and AI Safety and PHI Stewardship. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Biobeat and Cadence not disclosed?
At the last review, at least one of Biobeat and Cadence published thin or absent detail on Model Supply Chain Disclosure and AI Liability and Recourse. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Remote Monitoring & Chronic Care page.
The pigmentation problem sits on one side of this pair and it is consequential: optical vital sign measurement performs differently across skin tones, and Biobeat publishes no subgroup analysis for a device whose readings drive automated early warning alerts rather than a display. Ask for it explicitly. Cadence publishes no security attestation, trust centre, retention position or training use statement, and its record system integration is claimed without documentation. Neither publishes pricing or a unit of pricing.